Last reviewed · How we verify
Moderate to severe plaque psoriasis and ulcerative colitis
Approved treatments
- Chronic- PF-06480605 50 mg SC Q4W · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to severe plaque psoriasis and ulcerative colitis patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to severe plaque psoriasis and ulcerative colitis treatment landscape brief
- Moderate to severe plaque psoriasis and ulcerative colitis treatment updates RSS
Frequently asked questions about Moderate to severe plaque psoriasis and ulcerative colitis
What drugs treat Moderate to severe plaque psoriasis and ulcerative colitis?
Tracked treatments include Chronic- PF-06480605 50 mg SC Q4W.
What is the treatment for Moderate to severe plaque psoriasis and ulcerative colitis?
Standard treatment for Moderate to severe plaque psoriasis and ulcerative colitis includes Chronic- PF-06480605 50 mg SC Q4W. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderate to severe plaque psoriasis and ulcerative colitis patent cliff · Moderate to severe plaque psoriasis and ulcerative colitis CI report
- Treatment: Chronic- PF-06480605 50 mg SC Q4W · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing